Eupraxia Reports Positive Phase 1b/2a RESOLVE Data for EP-104GI in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals announced positive symptom response data from the ongoing Phase 1b/2a RESOLVE trial of EP-104GI in patients with Eosinophilic Esophagitis (EoE). For the first time, the company reported data on odynophagia (painful swallowing), showing that the proportion of patients in Cohorts 7-9 experiencing moderate to severe odynophagia decreased from 62% at baseline to 25% at weeks 24 through 52. Notably, no patients reported severe odynophagia at the 24 and 52-week timepoints. Similarly, moderate to severe dysphagia (difficulty swallowing) was reduced from 77% at baseline to 25% at 52 weeks. EP-104GI continues to be well-tolerated across over 130 treated patients, with no treatment-emergent or procedure-related serious adverse events (SAEs) reported. The drug utilizes the company's proprietary Diffusphere technology for local, controlled delivery. Eupraxia anticipates an interim readout from the randomized, placebo-controlled Phase 2b portion of the RESOLVE trial in Q4 2026.